These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 16455632)

  • 1. Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET.
    Kwee SA; Wei H; Sesterhenn I; Yun D; Coel MN
    J Nucl Med; 2006 Feb; 47(2):262-9. PubMed ID: 16455632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of step-section histopathology to evaluate 18F-fluorocholine PET sextant localization of prostate cancer.
    Kwee SA; Thibault GP; Stack RS; Coel MN; Furusato B; Sesterhenn IA
    Mol Imaging; 2008; 7(1):12-20. PubMed ID: 18384719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate cancer localization with 18fluorine fluorocholine positron emission tomography.
    Kwee SA; Coel MN; Lim J; Ko JP
    J Urol; 2005 Jan; 173(1):252-5. PubMed ID: 15592091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual-phase (18)F-fluorocholine PET/CT to detect locoregional recurrence of prostate cancer: comparison between each time point of imaging and a summation scan.
    Tong AK; Zhang ZX; Zaheer S; Yan XS
    Clin Imaging; 2016; 40(3):486-91. PubMed ID: 27133692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The value of dual time point (18)F-FDG PET imaging for the differentiation between malignant and benign lesions.
    Lan XL; Zhang YX; Wu ZJ; Jia Q; Wei H; Gao ZR
    Clin Radiol; 2008 Jul; 63(7):756-64. PubMed ID: 18555033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three-phase 18F-fluorocholine PET/CT in the evaluation of prostate cancer recurrence.
    Steiner Ch; Vees H; Zaidi H; Wissmeyer M; Berrebi O; Kossovsky MP; Khan HG; Miralbell R; Ratib O; Buchegger F
    Nuklearmedizin; 2009; 48(1):1-9; quiz N2-3. PubMed ID: 19212605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis.
    Farsad M; Schiavina R; Castellucci P; Nanni C; Corti B; Martorana G; Canini R; Grigioni W; Boschi S; Marengo M; Pettinato C; Salizzoni E; Monetti N; Franchi R; Fanti S
    J Nucl Med; 2005 Oct; 46(10):1642-9. PubMed ID: 16204714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Narrow time-window dual-point 18F-FDG PET for the diagnosis of thoracic malignancy.
    Conrad GR; Sinha P
    Nucl Med Commun; 2003 Nov; 24(11):1129-37. PubMed ID: 14569166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The value of 18F-choline PET/CT in patients with elevated PSA-level and negative prostate needle biopsy for localisation of prostate cancer.
    Igerc I; Kohlfürst S; Gallowitsch HJ; Matschnig S; Kresnik E; Gomez-Segovia I; Lind P
    Eur J Nucl Med Mol Imaging; 2008 May; 35(5):976-83. PubMed ID: 18188560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods?
    Pöpperl G; Kreth FW; Herms J; Koch W; Mehrkens JH; Gildehaus FJ; Kretzschmar HA; Tonn JC; Tatsch K
    J Nucl Med; 2006 Mar; 47(3):393-403. PubMed ID: 16513607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Single center experience of (18F)-fluorocholine positron emission tomography: analysis of its impact on salvage local therapy in patients with prostate adenocarcinoma].
    Moussaid Y; Bonardel G; Jacob J; Métivier D; Gontier E; Bauduceau O; Durand X; Fayolle M; Houlgatte A; Foehrenbach H; Védrine L; Chargari C
    Cancer Radiother; 2013; 17(4):259-64. PubMed ID: 23702489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients.
    Beheshti M; Imamovic L; Broinger G; Vali R; Waldenberger P; Stoiber F; Nader M; Gruy B; Janetschek G; Langsteger W
    Radiology; 2010 Mar; 254(3):925-33. PubMed ID: 20177103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does dual-time-point
    Wu B; Zhao Y; Zhang Y; Tan H; Shi H
    Hell J Nucl Med; 2017; 20(1):79-82. PubMed ID: 28315913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can dual-time-point 18F-FDG PET/CT differentiate malignant salivary gland tumors from benign tumors?
    Toriihara A; Nakamura S; Kubota K; Makino T; Okochi K; Shibuya H
    AJR Am J Roentgenol; 2013 Sep; 201(3):639-44. PubMed ID: 23971458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Differentiation of malignant and benign superficial lymph nodes by dual time point 18F-FDG PET].
    Su MG; Fan QP; Tian Y; Li FL; Yang XC; Li L; Fan CZ; Tian R
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 May; 40(3):517-20. PubMed ID: 19627018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-fluoride PET/CT for bone scanning. Role of attenuation correction.
    Nagarajah J; Dannat T; Hartung V; Bockisch A; Rosenbaum-Krumme S
    Nuklearmedizin; 2012; 51(3):84-7. PubMed ID: 22366817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of combination of contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography for evaluation of ovarian masses.
    Tsuboyama T; Tatsumi M; Onishi H; Nakamoto A; Kim T; Hori M; Sakane M; Hori Y; Morii E; Hatazawa J; Tomiyama N
    Invest Radiol; 2014 Aug; 49(8):524-31. PubMed ID: 24637584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of delayed 18F-FDG PET in differential diagnosis for malignant soft-tissue tumors.
    Hamada K; Tomita Y; Ueda T; Enomoto K; Kakunaga S; Myoui A; Higuchi I; Yoshikawa H; Hatazawa J
    Ann Nucl Med; 2006 Dec; 20(10):671-5. PubMed ID: 17385305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma.
    Schuster DM; Votaw JR; Nieh PT; Yu W; Nye JA; Master V; Bowman FD; Issa MM; Goodman MM
    J Nucl Med; 2007 Jan; 48(1):56-63. PubMed ID: 17204699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accuracy of PET for diagnosis of solid pulmonary lesions with 18F-FDG uptake below the standardized uptake value of 2.5.
    Hashimoto Y; Tsujikawa T; Kondo C; Maki M; Momose M; Nagai A; Ohnuki T; Nishikawa T; Kusakabe K
    J Nucl Med; 2006 Mar; 47(3):426-31. PubMed ID: 16513611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.